
Midostaurin

Printed from https://www.cancerquest.org/node/6389 on 11/14/2026



Brand name: Rydapt
IUPAC: (9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-

diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiamzonine-1-one
FDA approval: Yes
Manufacturer Link
Usage:

Midostaurin is a oral prescription medication used in the treatment of acute myeloid leukemia and is often used in conjunction with a variety of chemotherapy treatments. Typically, patients are told to take Midostaurin twice a day, but this is up to the physician's discretion.1

---

1 Treatment Information. (n.d.). Retrieved July 18, 2017, from https://www.us.rydapt.com/interested-in/treatment-information/?site=43700018488751000&source=01030&gclid=CliampKXk9UCFSKNswodGb8INw&gclsrc=ds

Mechanism:

Midostaurin is a protein kinase inhibitor used to treat acute myeloid leukemia. This drug works by preventing the transfer of phosphate to protein building cells. By altering the protein building capabilities of cancerous cells, Midostaurin helps limit the progression and spread of cancer cells.1

Sphere Stick Line Cross Rotate

---

1 FDA Approved Rydapt. (n.d.). Retrieved July 18, 2017, from https://www.us.rydapt.com/

Side effects:

The most common side effects associated with the use of Midostaurin include: low white blood cell counts with fever, nausea, redness and sores, headache, bruising, high sugar levels and upper respiratory issues.1

---

1 Treatment Information. (n.d.). Retrieved July 18, 2017, from https://www.us.rydapt.com/interested-in/treatment-information/?site=43700018488751000&source=01030&gclid=CliampKXk9UCFSKNswodGb8INw&gclsrc=ds

Contraindications:

It is important to alert your doctor if have heart or lung problems, are pregnant or plan to become pregnant, as these conditions can have an adverse effect in the use of Midostaurin. Also important to note are the issues that can occur in breastfeeding and fertility, which are further outlined on the manufacturers website.1

---

1 Treatment Information. (n.d.). Retrieved July 18, 2017, from https://www.us.rydapt.com/interested-in/treatment-information/?site=43700018488751000&source=01030&gclid=CliampKXk9UCFSKNswodGb8INw&gclsrc=ds